A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma

Leukemia

Volumn 27, Issue 6, 2013, Pages 1419-1422

  Thomson, K J ^a,b   Kayani, I ^b   Ardeshna, K ^b   Morris, E C ^b   Hough, R ^a,b   Virchis, A ^b   Goldstone, A H ^b   Linch, D C ^a,b   Peggs, K S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE; VINBLASTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER RECURRENCE; DONOR; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HODGKIN DISEASE; HUMAN; LETTER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; TANDEM REPEAT; TUMOR BIOPSY;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878902372     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.318     Document Type: Letter

References (14)

1. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203-212.
2. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054. (Pubitemid 23114397)
3. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071. (Pubitemid 34680969)
4. Sweetenham JW,Carella AM, Taghipour G, Cunningham D, Marcus R, Della VA et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European group for blood and marrow transplantation. Lymphoma working party. J Clin Oncol 1999; 17: 3101-3109. (Pubitemid 29470638)
5. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish cooperative group. J Clin Oncol 2001; 19: 1395-1404. (Pubitemid 32202546)
6. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109: 2481-2489. (Pubitemid 46906468)
7. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116: 4934-4937.
8. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934-1941. (Pubitemid 40797503)
9. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2008; 26: 455-462. (Pubitemid 351171699)
10. Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007; 139: 70-80. (Pubitemid 47389932)
11. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011; 29: 971-978.
12. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on Interim-PET-Scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-1260.
13. Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 1824-1833.
14. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2011; 119: 1665-1670.